With a robust academic background including an MBA in Finance from NYU-Stern, and an MD from Delhi University, my journey in the financial world has been diverse and enriching. My postgraduate training in medicine was conducted at Harvard and Cornell affiliated hospitals, thus laying a solid foundation for my current expertise.As a registered investment advisor and professional money manager, I bring nearly a decade of experience in writing about income investing and biotech/pharma investing. My role at Vas ...

SUNNYVALE, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, and Scott Blumberg, CFO, will participate in a fireside chat at the upcoming 45th Annual TD Cowen Health Care Conference. The fireside chat will take place on Monday, March 3, 2025, at 6:50 a.m. Pacific Standard Time / 9:50 ...

SUNNYVALE, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the fourth quarter and full year of 2024 after the close of trading on Tuesday, February 25, 2025. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on Febru ...

SUNNYVALE, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Ceribell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming 43rd Annual J.P. Morgan Healthcare Conference. The presentation will take place on Monday, January 13, 2025, at 7:30 a.m. Pacific Standard Time. Event: 43rd Annual J.P. Morgan Healthcare Confere ...

A good strategy to spot quality under-the-radar stocks is to analyse some of the recent initial public offerings. If the growth outlook is promising, an early entry can translate into meaningful value creation. This initiating coverage discussesAnalyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving ...

Business Performance - Total revenue for the three months ended September 30, 2024, was $17,195 million, a 48% increase from $11,611 million in the same period of 2023[159]. - Product revenue for the three months ended September 30, 2024, increased by $4,557 million, or 52%, compared to the same period in 2023[162]. - Subscription revenue for the three months ended September 30, 2024, increased by $1,027 million, or 36%, compared to the same period in 2023[163]. - Gross profit for the three months ended September 30, 2024, was $15,011 million, a 54% increase from $9,726 million in the same period of 2023[166]. - Total revenue for the nine months ended September 30, 2024, was $46,910 million, a 46% increase from $32,094 million in the same period of 2023[161]. Financial Position - The company reported an accumulated deficit of $154.4 million as of September 30, 2024, with cash and cash equivalents of $14.1 million[140]. - The company has received aggregate gross proceeds of $151.0 million from sales of common stock and $35.0 million from term loans since inception[140]. - Net cash used in operating activities for the nine months ended September 30, 2024, was $25.068 million, compared to $22.484 million for the same period in 2023, reflecting an increase in net loss from $21.2 million to $27.9 million[174][176]. - Principal payments required on long-term debt outstanding as of September 30, 2024, were $20.0 million[179]. - Estimated contractual obligations for operating lease payments as of September 30, 2024, were $2.8 million due within 28 months[179]. Operating Expenses - Total operating expenses for the three months ended September 30, 2024, were $24,948 million, an increase of 48% from $16,890 million in the same period of 2023[159]. - General and administrative expenses increased by $4,039 million, or 81%, for the three months ended September 30, 2024, compared to the same period in 2023[171]. - Research and development expenses increased by $1,087 million, or 47%, for the three months ended September 30, 2024, compared to the same period in 2023[168]. - Sales and marketing expenses are anticipated to rise as the company increases its sales organization and market penetration in the U.S.[153]. Cash Flow - Net cash used in investing activities remained consistent at $1.1 million for both the nine months ended September 30, 2024 and 2023, primarily for equipment purchases[177]. - Net cash provided by financing activities increased significantly to $5.788 million in the nine months ended September 30, 2024, compared to $0.644 million in 2023, driven by $7.6 million in net proceeds from debt issuance[178]. Product and Market Development - As of September 30, 2024, the Ceribell System has been adopted by over 500 active accounts and has been used to care for over 100,000 patients[135]. - The Ceribell System aims to become the standard of care for seizure detection in approximately 5,800 acute care facilities in the U.S.[137]. - The Ceribell System integrates AI-powered algorithms for real-time assessment of seizure activity, enhancing patient care in acute settings[136]. - Revenue is generated from two sources: product revenue from disposable headbands and subscription revenue from monthly fees for the Clarity system[145]. - The company expects revenue fluctuations due to the success of its sales force in extending adoption of the Ceribell System and seasonal factors affecting patient volume[146]. - The company has dual sources for major components of the Ceribell headband, ensuring supply chain resilience[138]. Other Financial Metrics - Net loss for the three months ended September 30, 2024, was $(10,417) million, a 48% increase from $(7,054) million in the same period of 2023[159]. - Interest and other income (expense), net decreased by $590 million for the three months ended September 30, 2024, compared to the same period in 2023[173]. - The increase in operating assets for the nine months ended September 30, 2024, was $3.6 million, attributed to inventory purchases and accounts receivable due to increased sales[175]. - The net decrease in operating liabilities for the nine months ended September 30, 2024, was $1.5 million, primarily due to timing of payments[175]. - The company reported a net increase in operating assets of $4.9 million for the nine months ended September 30, 2023, indicating a similar trend in sales growth[176]. Research and Development - Research and development expenses are expected to increase as the company continues to improve its algorithm and expand clinical applications[151]. - The company has made no material changes to its significant accounting policies and estimates as described in the Prospectus[181].

Ceribell Reports Third Quarter 2024 Financial Results Sunnyvale, CA – November 12, 2024 – CeriBell, Inc. (Nasdaq: CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the quarter ended September 30, 2024. Third Quarter 2024 & Recent Highlights • Reported total revenue of $17.2 million in the third quarter of 2024, a 48% increase compared to the same period in 2023 • Achieve ...

SUNNYVALE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Scott Blumberg, CFO, will participate in a fireside chat at the upcoming Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum. The fireside chat will take place on Thursday, November 21, 2024, at 10:00 a.m. Pacific Standard Time / 1:00 p.m. ...